February 27, 2008 10:33 ET

Cancer Treatment Pioneer and Anti-Bioactive-Lipid Category Leader, Lpath, Sets Key Goals for 2008

SAN DIEGO, CA--(Marketwire - February 27, 2008) - The management of Lpath, Inc. (OTCBB: LPTN), the category leader in bioactive-lipids-based therapeutics, announced the company's key business goals and objectives for the 2008 year following review and discussion with the company's board of directors. They include:

A. ASONEP™ Drug Development Program for Cancer:

1.  Initiate and execute Phase 1 clinical program: Now with clearance from
    the FDA, the company soon will begin dosing cancer patients to
    establish a recommended Phase 2 dose.

2.  Determine Phase 2 efficacy trial protocol:  Aside from establishing a
    well-tolerated Phase 2 dose, the company plans to evaluate various
    evidence-based hypotheses regarding anti-cancer efficacy to maximize
    chances of success in a Phase 2 trial.

B. iSONEP™ Drug Development Program for Wet Age-related Macular Degeneration (AMD):

1.  Submit an Investigational New Drug application (IND) to the FDA for
    the use of iSONEP in Wet-AMD patients:  Although the company
    anticipates iSONEP will have broad-ranging efficacy across a wide swath
    of ocular indications, Lpath plans to initiate use of iSONEP in Wet-AMD
    patients because of the well understood pathophysiology of this disease
    and the established mechanisms of action of iSONEP.

2.  Initiate and execute iSONEP Phase 1 clinical program.  The primary
    objective of this Phase 1 trial will be to establish a well-tolerated
    Phase 2 dose.

3.  Initiate studies outlined in the NIH grant. Funds from this recently
    awarded grant of $1.4 million will be used primarily to study of the
    efficacy of iSONEP.

C. Lpathomab™ Drug Development Program:

1.  Identify lead (humanized) candidate.  The company recently announced
    successful humanization of its LPA antibody and will soon choose which
    of the humanized variants will be our lead candidate.

2.  Evaluate various models of fibrosis, cancer, and neuropathic pain to
    determine our lead systemic indication.  The company recently
    demonstrated compelling efficacy of Lpathomab in prevention and
    intervention models of pulmonary fibrosis.  Studies in cancer and
    neuropathic pain are ongoing.

3.  Evaluate various mechanisms of action in the eye to determine a lead
    ocular indication. Lpathomab has already demonstrated strong anti-
    angiogenic activity in animal models of Wet AMD and will assess the
    drug candidate's anti-fibrotic and anti-inflammatory effects as well
    during 2008.

4.  Begin cell-line development of Lpathomab. Cell-line development is a
    key step towards larger-scale manufacturing of the antibody.

5.  Complete IND-enabling studies to support one or more IND applications
    in 2009.
D. 2008 Goals Relating to Leveraging Lpath's Overall Value:

1.  Leverage the value of ASONEP by confirming efficacy in animal models
    of human multiple sclerosis (and other systemic disease indications).

2.  Leverage the value of iSONEP by confirming efficacy in specific models
    of diabetes- and glaucoma-related diseases, as well as in Dry AMD.

3.  Leverage Lpath's ImmuneY2™ drug-discovery engine by generating
    additional monoclonal antibodies against novel bioactive-lipid targets.

Lpath also has other important 2008 goals and objectives relating to corporate governance, infrastructure building, and business development designed to support the company's growth and success.

"Lpath has maintained an excellent record of achieving its stated goals and hitting major milestones," notes Scott Pancoast, Lpath president and CEO, "and we will strive to continue this high level of performance during the 2008 year and beyond."

About Lpath:

Lpath, Inc., headquartered in San Diego, California, is the category leader in lipidomics-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP™ (the systemic formulation of sonepcizumab) is an antibody against S1P that holds promise for the treatment of cancer, multiple sclerosis, and other diseases. A second product candidate, iSONEP™ (the ocular formulation of sonepcizumab), has demonstrated superior results in various preclinical AMD and retinopathy models. Lpath's third product candidate, Lpathomab™, is an antibody against LPA, a key bioactive lipid that has been long recognized as a valid disease target. The company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2™ drug-discovery engine, which the company is using to add to its pipeline. For more information, visit

About Forward-Looking Statements:

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that results will be timely, necessary regulatory approvals will be obtained, the proposed treatments will prove to be safe or effective, or required clinical trials will be ultimately successful. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, our limited experience in the development of therapeutic drugs, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on research grants, current and future competition, and other risks described from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.